PEDIATRICS Vol. 76 No. 1 July 1985, pp. 142
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BOWEN, F. W.
Right arrow Articles by JOHNSON, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BOWEN, F. W., JR
Right arrow Articles by JOHNSON, L.

E-Ferol

FRANK W. BOWEN JR MD1 and LOIS JOHNSON MD1

1 Section on Newborn Pediatrics, Pennsylvania Hospital, Eighth and Spruce Sts, Philadelphia, PA 19107

To the Editor.—

Phelps' commentary, "E-Ferol: What Happened and What Now?"1 is an important reminder of the danger of using untested drugs. We feel, however, some points of clarification are needed.

First, Phelps cited Myers et al2 as using 1.1 mg/kg/d of E-acetate IV and raising serum E levels to 6 mg/dL in preterm infants. This is misquoted. Myers et al used 10 mg/kg of vitamin E over one hour (dl-agr-tocopherol [Hoffman LaRoche] not E-acetate) and achieved levels of 0.6 mg/dL not 6 mg/dL at the end of the infusion.